Stroke, Vol 25, 1755-1759, Copyright © 1994 by American Heart Association
BACKGROUND AND PURPOSE: There is no acute therapy proven to be of benefit
for ischemic stroke. Ancrod is a potentially effective therapy because of
the advantageous consequences of fibrinogen lowering. METHODS: We studied
the safety and efficacy of ancrod in patients with acute ischemic stroke
administered within 6 hours of stroke onset. In a double-blind, randomized,
placebo-controlled trial 64 patients received intravenous ancrod and 68
received placebo for 7 days. Neurological outcome, disability, and brain
infarct volume were measured. RESULTS: There was no significant difference
in overall mean scores on the Scandinavian Stroke Scale. No increase in
bleeding occurred in the ancrod-treated patients. The target reduction of
plasma fibrinogen levels of less than 100 mg/dL was achieved in only 15
(23%) of 64 ancrod-treated patients. Those patients with ancrod-induced
6-hour fibrinogen levels 130 mg/dL or less had a marginally significantly
better neurological outcome on the Scandinavian Stroke Scale, mortality,
and Barthel Index than ancrod-treated patients with higher fibrinogen
levels. CONCLUSIONS: Ancrod appears safe and potentially effective when
administered to patients within 6 hours of onset of ischemic stroke.
ARTICLES
Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators
This article has been cited by other articles:
 |
|
 |
|
  D. E. Levy, G. J. del Zoppo, B. M. Demaerschalk, A. M. Demchuk, H.-C. Diener, G. Howard, M. Kaste, A. M. Pancioli, C. Spatareanu, and W. W. Wasiewski Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program Stroke, December 1, 2009; 40(12): 3796 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Wasiewski To Phase 3 or Not to Phase 3? Stroke, May 1, 2009; 40(5): 1553 - 1554. [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ergin and N. Ergin Is Thrombolytic Therapy Associated With Increased Mortality?: Meta-analysis of Randomized Controlled Trials Arch Neurol, March 1, 2005; 62(3): 362 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119 (2009): 300S - 320S. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, H. S. Jorgensen, and D. T. Wade Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice Stroke, June 1, 2000; 31(6): 1429 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Sherman, R. P. Atkinson, T. Chippendale, K. A. Levin, K. Ng, N. Futrell, C. Y. Hsu, D. E. Levy, and for the STAT Participants Intravenous Ancrod for Treatment of Acute Ischemic Stroke: The STAT Study: A Randomized Controlled Trial JAMA, May 10, 2000; 283(18): 2395 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development Stroke, December 1, 1999; 30(12): 2752 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Pell, M. F. Lythgoe, D. L. Thomas, F. Calamante, M. D. King, D. G. Gadian, R. J. Ordidge, and G. A. Rosenberg Reperfusion in a Gerbil Model of Forebrain Ischemia Using Serial Magnetic Resonance FAIR Perfusion Imaging • Editorial Comment Stroke, June 1, 1999; 30(6): 1263 - 1270. [Abstract] [Full Text] [PDF]
|
|